Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | Unknown | — |
The patient received the second dose of RabAvert vaccine in the middle of the night between day three to day four; Case reference number US-BN-2024-002407 is a spontaneous case initially received from consumer via Med Communication (reference number USBAV24-2110) on 26-Aug-2024 and concerns a female patient of unknown age. The patient's medical history and concomitant medication were not provided. On an unspecified date, the patient received the first dose of RabAvert (batch number: unknown), at an unknown dose, route or site of administration, for rabies vaccination. As reported, the patient went to emergency room (ER) for the first dose and was told that following doses could be administered in urgent care. The patient was out of town when got first dose of RabAvert and found that it was very hard to find any urgent care in patient's area that carries this brand of vaccine. On an unspecified date, reported as in the middle of the night, between day three and day four, the patient received the second dose of RabAvert (batch number: unknown), at an unknown dose, route or site of administration (explicitly coded ' Inappropriate schedule of vaccine administered'). As reported, the patient went where the first dose was administered, for fear of keeping the same manufacture through the series. At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine. No further information was provided.; Reporter's Comments: A female patient of unknown age received the second dose of RabAvert for rabies vaccination, reported as in the middle of the night, between day three and day four, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unknown age received the second dose of RabAvert for rabies vaccination, reported as in the middle of the night, between day three and day four, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse event due to RabAvert vaccine. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: NONE